ARA-290 (16mg) Research Peptide: An EPO‑Derived Non‑Hematopoietic Peptide for Innate Repair Receptor Studies

If your research investigates tissue protection, neuropathic pain, or the molecular mechanisms of innate repair without the confounding effects of erythropoiesis, ARA-290 (16mg) research peptide — also known as Cibinetide — offers a precisely defined and mechanistically distinct synthetic tool. ARA‑290 is an 11‑amino‑acid engineered peptide that mimics the three‑dimensional structure of the helix B surface domain of erythropoietin (EPO). 

It was specifically designed to bind selectively to the innate repair receptor (IRR) — a heterodimeric complex composed of the EPO receptor (EPOR) and the β‑common receptor (CD131) — thereby activating the tissue‑protective and anti‑inflammatory arm of the EPO signalling system without stimulating red blood cell production. Despite a short plasma half‑life of approximately 2 minutes, ARA‑290 activates a molecular switch that triggers sustained biological effects observed in multiple preclinical models. This makes ARA-290 (16mg) research peptide a valuable tool for laboratories investigating neuroprotection, inflammation, tissue repair, metabolic regulation, and the biology of aging.

At Chinese Grey Peptides, we supply high‑purity ARA-290 (16mg) research peptide to research institutions and wholesale buyers across the United Kingdom, France, Germany, Spain, Sweden, Italy, and the USA. Every batch is lyophilised, HPLC‑verified to >99% purity, and accompanied by a Certificate of Analysis (COA), ensuring your investigations into innate repair signalling, neuroprotection, and tissue protection begin with uncompromising quality.

What Is ARA‑290 and How Does It Work?

To fully appreciate the research potential of ARA-290 (16mg) research peptide, it is essential to understand its biochemical design and the precise mechanism by which it exerts its pleiotropic tissue‑protective effects.

The 11‑Amino‑Acid EPO‑Derived Peptide

ARA‑290 (Cibinetide) is a synthetic linear peptide composed of 11 amino acids. Its sequence is {Pyr}‑Glu‑Gln‑Leu‑Glu‑Arg‑Ala‑Leu‑Asn‑Ser‑Ser (shortened as {Pyr}‑EQLERALNSS). Its molecular formula is C₅₁H₈₄N₁₆O₂₁, with a molecular weight of approximately 1,257.3 g/mol. It has a CAS number of 1208243‑50‑8.

The peptide was engineered from the helix‑B surface domain of the EPO molecule, identifying an 11‑amino‑acid sequence that selectively activates the tissue‑protective receptor without binding the classical homodimeric EPOR that drives erythropoiesis. This separation of function — between erythropoietic and tissue‑protective activities — was a key scientific insight that enabled the development of ARA‑290.

Mechanism of Action: Selective Innate Repair Receptor Agonism

The biological activity of ARA-290 (16mg) research peptide is mediated through its selective activation of the innate repair receptor (IRR):

Receptor Targeting: ARA‑290 binds selectively to the non‑haematopoietic EPO receptor, a heterodimeric complex composed of EPOR and the beta‑common receptor (βcR, CD131). This receptor is distinct from the classical homodimeric EPOR that drives erythropoiesis.

Tissue Protection Without Erythropoiesis: By engaging the IRR, ARA‑290 activates the tissue‑protective and anti‑inflammatory arm of the EPO signalling system without stimulating red blood cell production. This addresses the central challenge in EPO‑based research: achieving tissue‑protective effects without erythropoiesis.

Anti‑Inflammatory and Anti‑Apoptotic Signalling: ARA‑290 reduces inflammation and fibrosis, suppresses neuronal apoptosis, and mediates tissue protection through the β‑common receptor. IRR activation triggers two primary signalling cascades: anti‑inflammatory reprogramming through JAK2 phosphorylation of EPOR, and downstream modulation of pro‑inflammatory cytokines.

Short Half‑Life, Sustained Effects: Despite a plasma half‑life of approximately 2 minutes, ARA‑290 activates a molecular switch that triggers sustained biological effects observed in multiple preclinical models and clinical trials.

Research Note: The Innate Repair Receptor

The IRR is suggested to be a point of integration between the immune system and pain signalling (via nociception). ARA‑290 was designed to bind the IRR selectively, and this receptor configuration mediates EPO’s neuroprotective and cytoprotective effects.

Key Research Applications for ARA-290 (16mg)

ARA-290 (16mg) research peptide is a versatile tool with applications spanning several domains of biomedical research.

1. Neuroprotection & Ischaemic Research

ARA‑290 has demonstrated significant neuroprotective effects in models of cerebral ischaemia. Research has demonstrated:

• Cerebral Ischaemic Stroke: ARA‑290 exerts a neuroprotective action against cerebral ischaemic injury by suppressing neuronal apoptosis and inflammatory reactions in mice without motivating splenomegaly and erythropoiesis. The neuroprotective effect is mediated via the β‑common receptor.

• Neuropathic Pain: ARA‑290 dose‑dependently reduced allodynia coupled to suppression of the spinal microglia response. Phase II trials in sarcoidosis‑associated small‑fiber neuropathy showed improvements in neuropathic pain scores and corneal nerve fibre density.

• Experimental Autoimmune Neuritis: ARA‑290 greatly improved EAN recovery, improved nerve regeneration and remyelination, and suppressed nerve inflammation.

2. Inflammation & Immune Modulation Research

ARA‑290’s anti‑inflammatory properties make it a valuable tool for studying inflammatory signalling:

• Chronic Stress‑Induced Depression: ARA‑290 ameliorated chronic stress‑induced depression‑like behaviour in mice through, at least partially, its anti‑inflammatory effects.

• Cardiac Inflammation: Chronic ARA‑290 treatment mitigated age‑related increases in cardiac non‑myocyte to myocyte ratio, infiltrating leukocytes and monocytes, pro‑inflammatory cytokines, total NF‑κB, and p‑NF‑κB.

• Inflammatory Pathway Suppression: ARA‑290 selectively binds EPOR‑CD131, suppressing pro‑inflammatory factors, upregulating IL‑10/TGF‑β1, and enhancing macrophage efferocytosis.

3. Cardiovascular & Healthspan Research

ARA‑290 has been investigated for its effects on cardiovascular health and aging:

• Frailty Amelioration: Administration of ARA‑290 reduces cell and tissue inflammation, mitigates structural and functional changes within the cardiovascular system leading to amelioration of frailty and preserved healthspan.

• Cardioprotection: ARA‑290 reduces cardiac inflammation, attenuates age‑associated declines in heart function, and prolongs healthspan.

• Blood Pressure Regulation: ARA‑290 significantly blunted the age‑associated elevation in blood pressure and preserved left ventricular ejection fraction.

4. Metabolic & Diabetes Research

ARA‑290 has been investigated for its effects on metabolic control:

• Type 2 Diabetes: ARA‑290, a non‑erythropoietic peptide engineered from EPO, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.

• Metabolic Regulation: The peptide modulates inflammatory and metabolic parameters in diabetic models.

5. Wound Healing & Tissue Repair Research

ARA‑290 has been studied for its tissue‑protective effects:

• Wound Healing: ARA‑290 promotes skin wound healing without erythropoietic side effects by reducing apoptotic cell accumulation and enhancing macrophage efferocytosis.

• Acute Kidney Injury: ARA‑290 exerts beneficial effects in preclinical models of acute kidney injury.

• Endothelial Colony‑Forming Cells (ECFCs): ARA‑290 promotes ECFCs’ motility, proliferation, and resistance against H₂O₂‑induced apoptosis.

Chemical & Physical Specifications for ARA-290 (16mg)

Accurate characterisation of ARA-290 (16mg) research peptide is essential for reproducible experimental design.

Note: The 16 mg mass refers to the weight of the peptide in its lyophilised form. ARA‑290 is typically supplied as a TFA salt, which enhances aqueous solubility. The peptide has a plasma half‑life of approximately 2 minutes, but its protective effects are sustained through activation of the innate repair receptor. ARA‑290 is not FDA‑approved for human use and is supplied strictly for research use only (RUO).

Reconstitution & Handling Protocol for ARA-290 (16mg)

Proper reconstitution of ARA‑290 (16mg) research peptide is critical for maintaining its structural integrity and biological activity.

Step 1 – Preparation

• Bring the sealed ARA‑290 vial and your chosen diluent (sterile bacteriostatic water or sterile PBS, pH 5‑7) to room temperature. Condensation can degrade the lyophilised powder.

• Clean your work surface with 70% ethanol and lay out sterile syringes, alcohol wipes and a clean work mat.

Step 2 – Vial Sanitisation

• Wipe the rubber stopper of the ARA‑290 vial with a fresh 70% ethanol wipe. Allow the alcohol to evaporate completely before piercing.

Step 3 – Reconstitution

• Draw your desired volume of diluent into a sterile syringe. A common starting concentration for research applications is 16 mg per 1.6 mL of diluent, yielding a 10 mg/mL stock solution.

• Insert the needle and slowly inject the diluent against the inner glass wall. Do not spray directly onto the lyophilised powder.

• Gently swirl the vial until the solution is clear and fully dissolved. Do not shake vigorously, as shaking can cause denaturation.

Step 4 – Aliquoting & Storage

• Immediately after dissolution, aliquot the reconstituted ARA‑290 into single‑use sterile vials.

• Store aliquots at –20°C. Avoid repeated freeze‑thaw cycles, as peptides are susceptible to degradation.

• Once thawed, store at 2‑8°C and use within a short period.

Concentration Reference Table for ARA-290 (16mg)

Adjust diluent volume based on your experimental requirements. For cell culture applications, typical working concentrations may range from 0.1‑10 µM.

Storage & Stability Guidelines for ARA-290 (16mg)

Why Choose Chinese Grey Peptides for ARA-290 (16mg)?

As an authentic licensed peptide supplier based in the USA, we supply ARA-290 (16mg) research peptide and a wide range of research‑grade compounds under rigorous quality assurance protocols, fully aligned with Google’s E‑E‑A‑T standards (Experience, Expertise, Authoritativeness, Trustworthiness).

• Verified Purity: Independent HPLC analysis with purity guaranteed >99% for every batch.

• GMP‑Compliant Manufacturing: All peptides are synthesised under strict quality control conditions.

• Full Traceability: Batch‑specific Certificates of Analysis (COA) are available for every order.

• Wholesale Supply: We serve research institutions, laboratories, and wholesale buyers across the UK, EU, and USA with flexible volume pricing and reliable logistics.

• USA‑Based Regulatory Compliance: All products are supplied strictly as research‑grade chemicals for laboratory use only (RUO). ARA‑290 is not FDA‑approved for therapeutic use and has no active IND or NDA.

Researchers across the United States—including those at leading institutions—trust us for fast domestic delivery, transparent documentation and professional technical support.

FAQ: ARA-290 (16mg) Research Peptide

 What is ARA-290 (16mg) research peptide?
ARA‑290 (Cibinetide) is a synthetic 11‑amino‑acid peptide engineered from the helix‑B surface domain of erythropoietin (EPO). It is designed to bind selectively to the innate repair receptor (IRR) — a heterodimer of EPOR and CD131 — to mediate tissue‑protective and anti‑inflammatory effects without erythropoiesis.

What is the sequence and molecular weight of ARA‑290?
The sequence is {Pyr}‑Glu‑Gln‑Leu‑Glu‑Arg‑Ala‑Leu‑Asn‑Ser‑Ser ({Pyr}‑EQLERALNSS). Its molecular formula is C₅₁H₈₄N₁₆O₂₁, and its molecular weight is approximately 1,257.3 g/mol.

What are the primary research applications for ARA‑290?
ARA‑290 is used in neuroprotection and ischaemic research (cerebral stroke, neuropathic pain), inflammation and immune modulation research, cardiovascular and healthspan research, metabolic and diabetes research, and wound healing and tissue repair research.

What is the mechanism of action of ARA‑290?
ARA‑290 binds selectively to the innate repair receptor (IRR) — a heterodimer of EPOR and CD131 — activating the tissue‑protective and anti‑inflammatory arm of the EPO signalling system without stimulating red blood cell production.

 How does ARA‑290 differ from erythropoietin?
Unlike full‑length EPO, which drives erythropoiesis through the classical homodimeric EPOR, ARA‑290 selectively engages the heterodimeric IRR to mediate tissue protection without erythropoiesis. It has a plasma half‑life of approximately 2 minutes but activates sustained protective effects.

 What purity does your ARA-290 (16mg) meet?
Our ARA‑290 is tested to >99% purity by HPLC. A Certificate of Analysis (COA) is supplied with every order.

 How should I reconstitute ARA-290 (16mg)?
Reconstitute with sterile bacteriostatic water or sterile PBS (pH 5‑7). Allow the vial to reach room temperature, then slowly inject the diluent against the inner glass wall and swirl gently. Do not shake. A typical starting concentration is 10 mg/mL.

How should I store reconstituted ARA‑290?
Reconstituted ARA‑290 should be stored at 2‑8°C for short‑term use. For longer storage, aliquot immediately into single‑use vials and store at –20°C for up to 3 months. Avoid repeated freeze‑thaw cycles.

 Is ARA‑290 research peptide legal to purchase in the USA?
Yes. ARA‑290 is a laboratory reagent sold for research use only (RUO). It is fully legal to purchase, possess, and use in the United States for legitimate in‑vitro or in‑vivo scientific research, provided it is not marketed with therapeutic claims. Note: ARA‑290 is not FDA‑approved for therapeutic use and has no active IND or NDA.

 Does Chinese Grey Peptides ship internationally?
Yes. We ship across the UK, Europe (France, Germany, Spain, Sweden, Italy), and the USA from our US warehouse. Wholesale pricing is available for bulk orders.

1. Shop Page
2. Bulk Orders Page
3. Contact Page
4. Shipping & Return Page
5. Peptide Purity Page

• PubChem Cibinetide / ARA290
• NCBI MeSH Cibinetide
• IUPHAR Cibinetide ligand page
• FDA Gram Peptides warning letter
• Google Product Structured Data
• Rank Math WooCommerce Product Schema

Ships to USA, Canada, UK & Europe

Chinese Grey Peptides supports shipping to the USA, Canada, the United Kingdom, France, Germany, Spain, Sweden, Italy, and Europe where permitted.

Shipping support may include:

• Order processing updates
• Packaging support
• Tracking information where available
• Wholesale shipment planning
• Destination-based shipping review
• Customer support during transit

Shipping times may vary by order size, carrier, destination, customs process, product status, and local requirements.

Why Choose Chinese Grey Peptides?

Chinese Grey Peptides focuses on quality, support, and clear communication. We help buyers review product details before placing an order.

Customers choose us for:

• Professional peptide supplier support
• Small and wholesale order options
• Product documentation support
• HPLC testing information where available
• Mass Spectrum documentation where available
• International shipping support
• Responsive communication
• Clear order assistance before payment

We aim to make the buying process transparent, professional, and documentation-focused.

Important Compliance Notice

ARA-290 16mg may be regulated differently depending on the country, product type, labeling, intended use, buyer type, and destination. Chinese Grey Peptides does not provide medical advice, dosing instructions, injection guidance, neuropathy claims, pain claims, inflammation claims, tissue-repair claims, recovery claims, anti-aging claims, performance claims, disease claims, treatment claims, or personal-use recommendations.

Customers are responsible for understanding and following all local laws, import rules, prescription requirements, compounding rules, sport-governing rules, and permitted-use requirements before ordering.

From its origin as an engineered fragment of the helix‑B domain of erythropoietin to its well‑characterised role as a selective agonist of the innate repair receptor, ARA-290 (16mg) research peptide provides a precisely defined and mechanistically distinct platform for advanced neuroprotection, inflammation, and tissue repair research.

Its ability to engage the tissue‑protective arm of the EPO signalling system without erythropoiesis — supported by peer‑reviewed research published in PMC, Frontiers in Cardiovascular Medicine, CNS Neuroscience & Therapeutics, and other authoritative journals — makes it a valuable addition to any laboratory investigating neuroprotection, inflammatory signalling, tissue regeneration, or the biology of aging. By choosing high‑purity, lab‑verified ARA-290 (16mg) research peptide from Chinese Grey Peptides, you ensure that your research is built on a foundation of quality, reproducibility, and scientific integrity.

Ready to advance your research with ARA-290 (16mg)? Browse our product catalogue, request a wholesale quote, or contact our support team today to discuss your laboratory’s specific needs. Place your order now and receive GMP‑grade ARA‑290 delivered directly to your facility in the USA, UK, or Europe.ARA-290 (16mg)